MIRA
INFORM REPORT
|
Report Date : |
28.07.2008 |
IDENTIFICATION
DETAILS
|
Name : |
KUHNIL PHARM. CO., LTD. |
|
|
|
|
Registered Office : |
297-5, Gunseo-ri, Jiksan-eup, Cheonan-si, Chungcheongnam-do |
|
|
|
|
Country : |
Korea |
|
|
|
|
Financials (as on) : |
31.12.2007 |
|
|
|
|
Date of Incorporation : |
12.23.1955 |
|
|
|
|
Com. Reg. No.: |
312-81-06060 |
|
|
|
|
Legal Form : |
Company Limited by Shares |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Medicaments |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Basic
|
Company
Name |
KUHNIL
PHARM. CO., LTD. |
|
Registered Address |
297-5,
Gunseo-ri, Jiksan-eup, Cheonan-si, Chungcheongnam-do, Korea |
|
Zip Code |
330-811 |
|
Tel |
+82-41-580-5800 |
|
Fax |
+82-41-580-5807 |
|
E-mail |
kuhnil@kuhnil.com;webmaster@kuhnil.co.kr |
|
Website |
www.kuhnil.com |
|
Trading Address-Seoul Office |
237-12,
Gongdeok 2-dong, Mapo-gu, Seoul, Korea (P.O.BOX 578) |
|
Tel |
+82-2-714-0091 |
|
Fax |
+82-2-719-0493 |
|
Other Address-R&D Center |
Rm.908, Woolim Lions Valley, 680, Gasan-dong, Geumcheon-gu, Seoul,
Korea |
|
Type |
Export/Import |
|
Industry |
Manufacture of Medicinal Medicaments |
|
Main Business |
The liver Medicine For Promoting Nutrition, Gastritis Cure, Travail
Antiphlogistic |
|
Established (mm/dd/yyyy) |
12/23/1955 |
The Subject owns
the premises of registered HQ address & R&D Center.
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antibiotics(51101500) |
|
Sell |
Tetracycline(51101509) -Analgesics Antiinflammatory
Agents |
|
Sell |
Acetylcysteine(51161701) |
|
Sell |
Formulas and products for nutritional support(42231800) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Dietary supplements and nutritional therapy products(51191900) |
|
Sell |
Corticosteroids(51181700) |
|
Sell |
Antiulcer and related gastrointestinal GI drugs(51171900) |
|
Sell |
Cough and cold and antiallergy products(51161800) |
CEO’s
|
Name |
Kim Young-Joong |
|
Address |
237, Myeongnyun-dong 2-ga, Jongno-gu, Seoul
110-767 Korea |
|
Date of Birth |
06/05/1969 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital |
4,600,000,000 KRW |
|
Employees |
310 |
|
Formation |
Co., Ltd., by shares |
|
Bank Details |
Shinhang Bank-Shinchon Branch Hana Bank-Shincon Branch Woori Bank-Mapo Buk Branch |
|
Corporate Registered No. |
131111-0002011 |
|
Business Registered No. |
312-81-06060 |
|
Permit & Licenses |
Int’l Trade No.: 568243 |
|
Shareholder Position |
Kim Yong-Ok and his family have 99.00% of
total shares. |
|
Company History |
12/23/1955 Incorporated 04/14/1997 Changed company name to the
present name |
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Day |
|
President & CEO |
Mr. |
Kim Young-Joong |
Male |
Korean |
05/20/2005 |
|
Director |
Mr. |
Kim Yong-Ok |
Male |
Korean |
05/20/2002 |
|
Director |
Mr. |
Kim Sun-Soo |
Male |
Korean |
05/20/2002 |
|
Director |
Mr. |
Lee Jae-Keun |
Male |
Korean |
- |
|
Auditor |
Mr. |
Sun Byung-Jin |
Male |
Korean |
11/02/1933 |
Financials
Unit: KRW
|
Year |
Sales |
Assets |
Net income |
|
71,523,292,381 |
66,913,947,423 |
4,976,184,516 |
|
|
2006 |
67,302,244,048 |
62,942,434,793 |
2,200,289,180 |
|
2005 |
64,990,841,633 |
62,214,016,597 |
3,596,441,520 |
|
2004 |
57,871,563,273 |
55,776,419,451 |
2,517,564,196 |
Financial Description
Unit: KRW
|
Authorized
Capital |
5,000,000,000 |
|
Paid-Up
Capital |
4,600,000,000 |
|
Total Issues Shares |
920,000 |
Balance
Sheet
|
Unit : Korean Won |
As of 12/31/2007 |
As of 12/31/2006 |
As of 12/31/2005 |
|
Total Assets |
66,913,947,423 |
62,942,434,793 |
62,214,016,597 |
|
Current Assets |
38,433,728,871 |
35,181,763,726 |
38,294,163,566 |
|
-Quick Assets |
29,551,992,766 |
25,750,473,908 |
27,995,212,787 |
|
-Inventories |
8,881,736,105 |
9,431,289,818 |
10,298,950,779 |
|
Fixed Assets |
28,480,218,552 |
27,760,671,067 |
23,919,853,031 |
|
-Investment |
6,594,840,040 |
4,619,536,664 |
5,202,175,804 |
|
-Tangibles |
18,686,482,476 |
19,492,426,448 |
16,609,229,056 |
|
-Intangibles |
1,828,995,036 |
2,341,192,855 |
2,108,448,171 |
|
-Others |
1,369,901,000 |
1,307,515,100 |
- |
|
Total Liabilities |
15,823,809,478 |
16,177,457,273 |
18,384,668,757 |
|
Current Liabilities |
12,579,686,473 |
12,321,765,188 |
15,959,437,715 |
|
Fixed Liabilities |
3,244,123,005 |
3,855,692,085 |
2,425,231,042 |
|
Capital Stock |
4,600,000,000 |
4,600,000,000 |
4,600,000,000 |
|
Capital Surplus |
717,849,595 |
717,849,595 |
717,849,595 |
|
Profit Surplus |
45,687,971,941 |
40,711,787,425 |
38,511,498,245 |
|
Capital Adjustment |
84,316,409 |
735,340,500 |
- |
|
Total Equity |
51,090,137,945 |
46,764,977,520 |
43,829,347,840 |
|
Liab. &
Shareholder’s Equity |
66,913,947,423 |
62,942,434,793 |
62,214,016,597 |
|
Current Liabilities |
12,579,686,473 |
12,321,765,188 |
15,959,437,715 |
|
Trade Payables |
3,065,539,793 |
2,704,180,833 |
2,487,490,343 |
|
Short-Term Borrowings |
2,500,000,000 |
4,150,000,000 |
4,594,276,500 |
|
Account Payables |
2,409,223,526 |
2,559,116,003 |
2,907,821,341 |
|
Advance Receipts |
31,334,395 |
15,000,000 |
15,106,421 |
|
Withholdings |
64,612,111 |
78,778,180 |
159,813,987 |
|
VAT Withhold |
1,157,101,348 |
1,030,239,447 |
1,193,483,005 |
|
Accrued Expenses |
13,570,684 |
20,766,295 |
7,576,374 |
|
Accrued Income Tax |
2,952,804,616 |
1,316,584,430 |
4,017,737,581 |
|
Current Portion of Long-Term
Debts |
- |
19,800,000 |
124,129,497 |
|
Guarantee Deposit Withhold |
385,500,000 |
427,300,000 |
452,002,666 |
|
Fixed
Liabilities |
3,244,123,005 |
3,855,692,085 |
2,425,231,042 |
|
Long-Term Borrowings |
800,000,000 |
1,358,000,000 |
19,800,000 |
|
Provision for Refund |
1,438,332,941 |
1,438,332,941 |
1,438,332,941 |
|
Provision for Severance &
Retirement |
1,471,704,410 |
1,474,098,120 |
1,286,196,460 |
Income
Statement
|
Unit : Korean Won |
As of 12/31/2007 |
As of 12/31/2006 |
As of 12/31/2005 |
|
Sales |
71,523,292,381 |
67,302,244,048 |
64,990,841,633 |
|
Cost of Sold Goods |
28,381,762,749 |
24,971,919,569 |
23,156,459,850 |
|
Gross Profit |
43,141,529,632 |
42,330,324,479 |
41,834,381,783 |
|
Selling & Admin. Expenses |
35,841,833,650 |
37,686,849,674 |
34,640,035,317 |
|
Operating Income |
7,299,695,982 |
4,643,474,805 |
7,194,346,466 |
|
Non-Operating Income |
3,316,512,861 |
2,865,454,440 |
2,946,526,354 |
|
Non-Operating expenses |
1,020,879,706 |
1,611,150,780 |
1,238,384,140 |
|
Ordinary Income |
9,595,329,137 |
5,897,778,465 |
8,902,488,680 |
|
Special Income |
- |
- |
- |
|
Income Before Taxes |
9,595,329,137 |
5,897,778,465 |
8,902,488,680 |
|
Income Taxes Expenses |
4,619,144,621 |
3,697,489,285 |
5,306,047,160 |
|
Net Income |
4,976,184,516 |
2,200,289,180 |
3,596,441,520 |
Cash
Flows
|
Unit : Korean Won |
As of 12/31/2007 |
As of 12/31/2006 |
As of 12/31/2005 |
|
Cash Flows from Operating |
5,391,787,857 |
3,826,415,724 |
4,047,547,206 |
|
-Net Income |
4,976,184,516 |
2,200,289,180 |
3,596,441,520 |
|
-Exp. without Cash Outflow |
4,327,879,595 |
4,334,230,252 |
2,891,526,823 |
|
-Revenue
without Cash Inflows |
(-)1,122,896,452 |
(-)653,321,212 |
(-)973,679,024 |
|
-Changes in
Asset/ & Liability |
(-)2,789,379,802 |
(-)2,054,782,496 |
(-)1,466,742,113 |
|
Cash Flows
from Investing |
(-)1,198,952,774 |
(-)5,712,617,636 |
(-)4,798,274,016 |
|
-Cash Inflow
from Investing |
3,371,575,451 |
5,077,555,939 |
1,645,687,343 |
|
-Cash
Outflows for Investing |
(-)4,570,528,225 |
(-)10,790,173,575 |
(-)6,443,961,359 |
|
Cash Flows
from Financing |
(-)2,269,600,000 |
764,891,337 |
473,550,331 |
|
-Cash
Inflows from Financing |
12,700,000,000 |
6,505,521,318 |
4,363,368,481 |
|
-Cash
Outflows from Financing |
(-)14,969,600,000 |
(-)5,740,629,981 |
(-)3,889,818,150 |
|
Increase/Decrease in Cash |
1,923,235,083 |
(-)1,121,310,575 |
(-)277,176,479 |
|
Cash at the Beginning of Year |
901,778,254 |
2,023,088,829 |
2,300,265,308 |
|
Cash at the End of Year |
2,825,013,337 |
901,778,254 |
2,023,088,829 |
Products, Technologies, Services
Description
|
Main
Products & Services |
Musculoskeletal System Antibiotics Gastrointestinal Products Cardiovascular Products Respiratory Products Neurology Products Endocrinology Products Anti-Allergy Products Ophthalmology Products Urology Products |
Trade
Partners
|
Competitors |
KYUNGDONG PHARM CO., LTD.(120111-0003765) DONGSUNG PHARMACEUTICAL
CO.,LTD(110111-0008200) BORYUNG PHARM CO.,LTD.(110111-0012560) SEOUL PHARMA CO.,LTD(130111-0008721) |
Related Parties (Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
PENMIX LTD(110111-2487498) (35.0% held by the subject company) JONGOH PHARMACY SEJIN BUILDING |
|
Cooperative Enterprise |
-License agreement with below companies; BIOPRO( GUILFORD) AND CUBIST , USA YM BIOSCIENCES , CANADA REGULON , GREECE MEFORYL ER , USV INDIA NOVARTIS(GERBER) , SWITZERLAND LESVI AND VINAS , SPAIN SMB AND IPR@D , FRANCE SENJU(BRONUCK®) , JAPAN PRONOVA(OMACOR®) , NORWAY KING PHARMACEUTICALS , USA BAUSCH&LOMB , USA TEDEC MEIJI , SPAIN BIOCODEX , FRANCE -Insured Company DONGBU INSURANCE CO., LTD(110111-0095285) |
Sales by
Region (Activity &
Markets)
The Subject deals with the companies in Japan, Singapore and Vietnam.
Court
Action
No.
News
Clipping
--
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.42.30 |
|
UK Pound |
1 |
Rs.84.03 |
|
Euro |
1 |
Rs.66.42 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)